Announcements Trials
Browse Landscape

Phase

Phase 1 2

Status

Terminated 2Completed 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Lymphoid 2Dermatologic 1

Conditions

Leukemia, Myeloid, Acute 117Myelodysplastic Syndromes 73Leukemia, Myelomonocytic, Chronic 34Leukemia 30Neoplasms 11Carcinoma, Non-Small-Cell Lung 11Precursor Cell Lymphoblastic Leukemia-Lymphoma 9Myeloproliferative Disorders 8Lymphoma, Non-Hodgkin 8Lymphoma 8Leukemia, Myelomonocytic, Acute 8Congenital Abnormalities 8Recurrence 7Multiple Myeloma 7Lymphoma, Large B-Cell, Diffuse 6Leukemia, Myelogenous, Chronic, BCR-ABL Positive 6Leukemia, Monocytic, Acute 6Leukemia, Erythroblastic, Acute 6Primary Myelofibrosis 5Lung Neoplasms 5Leukemia, Megakaryoblastic, Acute 5Leukemia, Lymphocytic, Chronic, B-Cell 5Hodgkin Disease 5Hematologic Neoplasms 5Anemia, Refractory, with Excess of Blasts 5Prostatic Neoplasms 4Myelodysplastic-Myeloproliferative Diseases 4Melanoma 4Lymphoma, Follicular 4Pancreatic Neoplasms 3

Interventions

Rituximab 134Cyclophosphamide 126Peripheral Blood Stem Cell Transplantation 74fludarabine phosphate 71Filgrastim 62Etoposide 56Bortezomib 44Vincristine 43Mycophenolic Acid 43Whole-Body Irradiation 42Cytarabine 42Cyclosporine 41Melphalan 38Doxorubicin 37Radiotherapy 36Busulfan 35ibrutinib 34Tacrolimus 34Methotrexate 33Prednisone 32Lenalidomide 30Bendamustine Hydrochloride 30Antilymphocyte Serum 27Dexamethasone 26Carmustine 26Granulocyte Colony-Stimulating Factor 23ibritumomab tiuxetan 20sargramostim 17fludarabine 17Methylprednisolone 16

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Completed × Lymphoma, Mantle-Cell × Azacitidine × Clear all
NCT04578600 2025-04-24

CC-486, Lenalidomide, and Obinutuzumab for the Treatment of Recurrent or Refractory CD20 Positive B-cell Lymphoma

University of California, Davis

Phase 1 Completed
8 enrolled
LymphoidOther hematologic neoplasm

Leukemia, Hairy Cell, Lymphoma, Follicular, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, B-Cell, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT00005639 2019-01-11

Azacitidine Plus Phenylbutyrate in Treating Patients With Advanced or Metastatic Solid Tumors That Have Not Responded to Previous Treatment

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 1 Completed
34 enrolled
DermatologicLymphoidOther hematologic neoplasm

Burkitt Lymphoma, Hodgkin Disease, Immunoblastic Lymphadenopathy, Lymphoma, Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Mycosis Fungoides, Sezary Syndrome, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large-Cell, Immunoblastic, Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Cutaneous, Lymphoma, Large-Cell, Anaplastic, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, Intraocular Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡